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Abstract
Purpose US licensing studies of subcutaneous IgG (SCIG)
calculate dose adjustments necessary to achieve area under
the curve (AUC) of serum IgG vs. time on SCIG that is non-
inferior to that on intravenous IgG (IVIG), within the FDA-
set limit of ±20 %. The results are interpreted as showing
that different SCIGs differ in bioavailability. We used three
approaches to determine if the bioavailabilities were actual-
ly different.
Methods Dose adjustments and AUCs from published li-
censing studies were used to calculate bioavailabilities using
the formula: Bioavailability (% of IVIG) = AUC(SCIG) ÷
AUC(IVIG) x 1/Dose Adjustment. We also compared the
increment in serum IgG concentration achieved with vary-
ing doses of SCIG in recent meta-analyses with the incre-
ment with different doses of IVIG, and determined the
serum IgG concentrations when patients switched SCIG
products at the same dose.
Results The actual bioavailabilities were: Gamunex® 65.0 %,
Hizentra® 65.5 %, Gammagard® 67.2 %, Vivaglobin®
69.0 %. Regression analyses of serum IgG vs. dose showed
that the mean increase in serum IgG resulting from a
100 mg/kg/month increment in SCIG dosing was 69.4 % of
the increase with the same increment in IVIG dosing
(84 mg/dL vs. 121 mg/dL). Patients switching SCIG prepara-
tions at the same dose had no change in serum IgG levels,
confirming that bioavailabilities of the SCIG preparations did
not differ.
Conclusions Decreased bioavailability appears to be a basic
property of SCIG and not a result of any manufacturing
process or concentration. Because serum IgG levels do not
vary with different SCIG products at the same dose, adjust-
ments are not necessary when switching products.
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Introduction
Because of uncertainty about which pharmacokinetic pa-
rameter: peak, trough or mean serum IgG concentration, if
any, should be matched when switching patients with pri-
mary immune deficiencies (PID) from intravenous IgG
(IVIG) to subcutaneous IgG (SCIG), the US Food and Drug
Administration (US FDA) requires matching the area under
the curve (AUC) of serum IgG vs. time on SCIG to that of
IVIG [1]. Adjusting the dose to achieve the same AUC is
considered necessary because of presumed differences in the
bioavailability of IgG and similar proteins when given by
the intramuscular (IM) or subcutaneous (SC) routes as com-
pared with the intravenous (IV) route [2]. Dose adjustments
of 120 % to 153 % have been used in different studies of
polyclonal SCIG, implying that the different products have
different bioavailabilities [3–6]. However, “non-inferiority”
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designs, which accept a margin of ±20 % of AUC, have
been employed, so the derived dose adjustments may not
reflect the actual bioavailability of different products [1].
This, in turn, might suggest that different manufacturing
processes alter the IgG molecules in different ways or that
more highly concentrated IgG solutions might behave dif-
ferently than less concentrated solutions, and that dose
adjustments may be necessary when switching from one
SCIG product to another. This study was carried out to
determine if, in fact, different SCIG preparations differ in
bioavailability.
SCIG is commonly used as replacement therapy in
patients with PID [3–8]. It has also been successfully tried
in autoimmune peripheral neuropathies [9]. Unlike IVIG,
SCIG initially forms a local depot and reaches the blood
stream indirectly through the lymphatic system, which sig-
nificantly slows down the absorption of IgG into the circu-
lation [10]. Several studies suggest that the bioavailability of
subcutaneously administered monoclonal antibodies, Fc
fusion proteins and polyclonal IgG may be reduced due to
degradation by tissue enzymes and/or non-covalent binding
to structural proteins of the extracellular matrix [2].
In spite of the lower bioavailability of SCIG compared
with IVIG, switching from IVIG to SCIG may be beneficial
for some patients, because SCIG administration: (i) over-
comes specific obstacles to the use of IVIG, such as the
requirements for venous access, trained personnel, and spe-
cialized facilities; (ii) allows more even distribution of doses
over time to avoid “wear-off” effects such as malaise,
fatigue, arthralgias/myalgias, and increased susceptibility
to infections towards the end of each dosing interval; and
(iii) provides freedom from infusion-related systemic ad-
verse events [7, 8]. In Europe, the IVIG monthly dose is
usually divided into four equal weekly doses when patients
are switched from IVIG to SCIG [11, 12]. However, the US
FDA requires that the monthly dose of SCIG be adjusted to
provide equivalent total monthly systemic exposure to IgG
on SCIG as compared with the previous IVIG therapy, as
assessed by AUC of serum IgG concentration over time [1].
Here we report the bioavailabilities of different individual
SCIG products calculated from the actual pharmacokinetic
data, rather than just the apparent dose adjustments neces-
sary to achieve AUCs within the 80 % margin accepted as
meeting the FDA’s criterion of “non-inferiority” [3–6]. The
results show that all SCIG products have remarkably similar
bioavailabilities. We also compared the mean slopes of the
lines of serum IgG vs. dose from large meta-analyses of
SCIG and IVIG studies and found that the ratio of those
slopes very closely approximates the results from the indi-
vidual SCIG licensing studies. Finally, to confirm the con-
clusions that different SCIG products have similar
bioavailabilities, we compared serum IgG levels in PID
patients who switched from one SCIG product to another
at the same dose, and found that the serum IgG levels did
not change. Together, the results suggest that: (i) decreased
bioavailability is a general property of IgG when it is ad-
ministered by the SC as compared to the IV route, (ii)
different SCIG products have similar bioavailabilities, and,
thus, (iii) dose adjustments are not necessary when switch-
ing between SCIG products.
Methods
In order to calculate the bioavailabilities of Hizentra® (20 %),
Vivaglobin® (16 %), Gamunex® (10 %), and Gammagard®
(10 %), we extracted data on the mean dosage adjustment,
AUC achieved with SCIG (AUCSCIG) on that adjusted dose,
and AUC on IVIG (AUCIVIG) from published reports of US
licensing trials in which PID patients already on stable IVIG
treatment regimens were switched to SCIG [3–6]. The mean
ratios between the AUCSCIG and the AUCIVIG were used to
calculate SCIG bioavailabilities using the formula:
Bioavailability % of IVIGð Þ ¼ AUCSCIG  AUCIVIGð Þ
 1 Dose Adjustment=
Data from a meta-analysis reporting the relationship be-
tween mean serum IgG trough levels and monthly IVIG
doses in 17 different studies which together included 676
PID patients on 14 different IVIG products were obtained
from Orange, et al. [13]. Data from a meta-analysis report-
ing the relationship between steady-state serum IgG concen-
trations and total monthly doses of SCIG in 9 different
studies, which together included 376 PID patients on 8 dif-
ferent products, were obtained from Orange et al. [14]. The
slopes of the lines of linear regression analyses for each
route of therapy were compared to determine the ratio of the
mean increment in serum IgG per 100 mg/kg/month incre-
ment in IgG dose. This ratio was then taken as an estimate of
the relative bioavailability of SCIG as compared to IVIG. In
the IVIG meta-analysis [13], the majority of patients had
either common variable immune deficiency (CVID; 49.3 %)
or X-linked agammaglobulinemia (XLA; 37.4 %). The
mean age in individual studies varied from 2.3 years to
44 years. Underlying PID diagnoses were not listed in the
SCIG pooled analysis, but it is likely that the predominant
diagnoses were also CVID and XLA. All studies included in
both meta-analyses had durations of at least 6 months. In
both analyses, a linear dependency between trough serum
IgG concentrations and IgG doses was observed [13, 14].
Finally, pharmacokinetic data from two prospective,
open-label studies conducted mainly in the European Union
(EU) and in the US, respectively, were used to calculate the
changes in serum IgG levels in PID patients switching
between different SCIG products. In the EU study [15], 19
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patients previously treated with stable weekly SCIG infu-
sion regimens (13 patients on Vivaglobin®, 4 patients on
Subcuvia® [16 %] and 2 patients on Gammanorm® [16 %])
were switched to an equal dose of Hizentra® (mean [±stan-
dard deviation; SD] of individual median doses:
120±36 mg/kg/week). Serum IgG levels were measured
immediately before infusions during three visits 3 to
6 months prior to switching to Hizentra®, at Weeks 1, 4,
8, 16 after switching to Hizentra® and every 4 weeks there-
after. The mean IgG levels were calculated for each patient
for the wash-in/wash-out period (Weeks 1–8), the steady-
state efficacy period (Weeks 16–24), and for the post-
efficacy period (Weeks 30–36), to be sure that a steady state
was achieved. The mean serum IgG levels were calculated
by averaging individual patient’s median values at each time
period. In the US study [16], 19 patients receiving steady-
state Vivaglobin® treatment were switched to an equal
weekly dose of Hizentra®. Due to dose rounding in several
cases, the mean (±SD) dose of Hizentra® was 1.04 times
higher than that of Vivaglobin®: 155±60 mg/kg/week vs.
150±60 mg/kg/week. Serum IgG levels were measured
8 weeks before switching to Hizentra® (Week 0), before
the last infusion of Vivaglobin® (Week 8), and twice after
the switch to Hizentra® (Weeks 12 and 24). In these studies,
no dose adjustments were made after switching to
Hizentra®. All measurements were performed in a single
CLIA-certified laboratory.
Results
Data extracted from the US licensing studies of SCIG prep-
arations [3–6] is summarized in Table I. The dose adjust-
ments used in the various studies were 137 % to 153 % and
the ratios for AUCSCIG/AUCIVIG actually achieved ranged
from 0.890 to 1.002. The bioavailabilities relative to IVIG
of the four SCIG preparations were calculated from these
data using the formula provided in Methods.
The results for all four SCIG preparations were very sim-
ilar: Hizentra® 65.5 %; Gammagard® 67.2 %; Gamunex®
65.0 %; and Vivaglobin® 69.0 % (Table I). The mean bio-
availability of these SCIG products was thus 66.7 % of IVIG,
with a SD of only ±1.8 % (Fig. 1).
To further study the bioavailability of a broader range of
different SCIG preparations as compared to a broader range of
IVIG preparations, we compared the slopes of linear regres-
sion lines for serum IgG vs. dose in recent meta-analyses of all
available IVIG and SCIG studies [13, 14]. The results are
presented in Fig. 2 (upper panels). The slope for the mean
increase in serum IgG levels resulting from a 100mg/kg/month
increment in the SCIG dose (84 mg/dL per 100 mg/kg/month)
was lower than the slope of the line of the mean increase in
trough serum IgG levels achieved with the same increment of
IVIG doses (121 mg/dL per 100 mg/kg/month) [13, 14]. In
striking similarity with the bioavailabilities calculated from the
four US licensing studies, the ratio of these slopes was 69.4%,
suggesting that this bioavailability is directly related to the SC
route of administration and not to specific properties of any
individual SC or IV preparation.
Based on the above results, we hypothesized that since
the bioavailabilities of different SCIG products were actual-
ly similar, switching between different SCIG products
would not result in changes in the steady-state serum IgG
levels, despite the different dose adjustments suggested by
their licensing studies. To test this hypothesis, we analyzed
steady-state serum IgG levels in two studies of PID patients
switched from other SCIG products to the same dose of
Hizentra®. In the EU study [15], PID patients (n=19) on stable
Table I Bioavailabilities of SCIG products
SCIG product Vivaglobin® Hizentra® Gamunex® Gammagard®
Reference Berger M et al.
2011 [3]
Berger M et al. 2011 [3]
Wasserman RL et al. 2011 [4]
Wasserman RL
et al. 2010 [5]
Wasserman RL
et al. 2011 [6]
Total number of patients, n 24 18 26 35a
Patients with CVID, n (%) 18 (75) 17 (94) n/a 27 (58)b
Age in years, median (range) 35 (9–61) 38.5 (10–60) n/a (13–75) n/a (14–77)
Reported AUCSCIG/AUCIVIG ratio 0.945 1.002 0.890 0.922
a
SCIG dose adjustment, % of IVIG dose 137.0 153.0 137.0 137.3a
Dose adjustment required to yield
AUCSCIG/AUCIVIG =1.00
c
145.0 152.7 153.9 148.9
Bioavailability, % of IVIG 69.0 65.5 65.0 67.2
AUC area under the curve; IVIG intravenous IgG; n number of patients; n/a not available; SCIG subcutaneous IgG
a ≥12-year-old patients only
b All treated patients (n=47)
c Calculated as: (SCIG dose adjustment, % of IV dose) ÷ (Reported AUCSCIG/AUCIVIG ratio)
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dosing regimens with Vivaglobin® (n=13), Subcuvia® (n=4),
or Gammanorm® (n=2) at a mean monthly dose of 120±
36 mg/kg/week were switched to the same weekly dose of
Hizentra®. The overall mean (±SD) serum IgG levels on the
other SCIG products was 850±140 mg/dL, while on Hizentra®
it was 830±120 mg/dL (a difference of only 2.4 %; Fig. 3).
The mean (±SD) steady-state serum IgG levels were
820±140 mg/dL to 850±120 mg/dL during the different stages
of the Hizentra® treatment period. The mean change in serum
IgG concentrations on Hizentra®, relative to the previous SCIG
products was −20 mg/dL (95 % CI: −49 mg/dL to +90 mg/dL).
In the US study [16], 19 patients on a mean weekly dose of
150±60mg/kg of Vivaglobin®were switched to Hizentra® at a
mean weekly dose of 155±60 mg/kg. The 4 % increase in dose
on Hizentra® was due to rounding in a few cases. The overall
mean (±SD) serum IgG levels on Vivaglobin® and Hizentra®
were not different (1150±270 mg/dL vs. 1130±270 mg/dL; a
difference of only 1.7 %, p = NS; Fig. 4). The mean (±SD)
serum IgG levels were 1160±290mg/dL and 1100±250mg/dL
at Weeks 12 and 24 of the study (4 and 16 weeks after the last
Vivaglobin® dose), respectively. The mean change of serum
IgG concentration during the Hizentra® treatment, relative to
the Vivaglobin® treatment, was -20 mg/dL (95 % CI:
-83 mg/dL to +43 mg/dL). The absence of a statistically
significant change in serum IgG levels after switching from
other SCIG preparations to Hizentra® (the 95% CI included 0
in both studies) allowed us to exclude the possibility that there
are differences in the bioavailabilities of different SCIG prep-
arations that are statistically or clinically significant.
Discussion
We present three lines of evidence which together suggest
that different commercial preparations of SCIG have very
similar bioavailabilities relative to that of IVIG. First, we
calculated actual bioavailabilities from available data
obtained in studies in which different dose adjustments were
used when switching from IVIG to SCIG to achieve the
target AUC established with IVIG [3–6]. Because the study
designs accepted “non-inferiority” with a margin of ±20 %
of this target, dose adjustments of 137 % have been accepted
in some product labels, which resulted in only 89 % of the
target AUC [3, 5, 6]. In contrast, the one licensing study in
which the AUCSCIG actually reached 100 % of the target
suggested that a dose adjustment of 153 % was necessary
with that product [4]. When the actual AUCs achieved with
the different adjusted doses are taken into account, it is
readily apparent that all of the preparations licensed for
SCIG use in the US have bioavailabilities within the range
65.0–69.0 % as compared to IVIG.
Next, we compared data from recent meta-analyses
which estimated the mean increase in serum IgG levels
achieved with increments in the dose of IgG given to PID
patients [13, 14]. Together, these analyses contain data from
26 studies, which included 1052 patients treated with 22
different IgG products. The results show that the mean
increase in the serum IgG concentrations with any given
increment in the IgG dose differs if the IgG is being given
by the SC as opposed to the IV route. The mean increase in
steady-state serum IgG level for every 100 mg/kg/month
increment in SCIG dose is 69.4 % of the increase in trough
level achieved with the same increment in the IVIG dose
(Fig. 2). Interestingly, although many more products and
patients, and a broader range of doses were included in these
meta-analyses than in the individual licensing studies, this
result closely matches the bioavailabilities of each of the
four individual preparations presented above (mean: 66.7 %
of IVIG; Table 1). Furthermore, the individual licensing
studies as well as the meta-analyses indicate that the bio-
availabilities of the highly concentrated SCIG preparations,
Vivaglobin® and Hizentra®, do not differ from those for
10 % IV products when given by the SC route. The reduc-
tion in bioavailability observed when the same 10 % prep-
arations are given by the SC route vs. the IV route also
supports the conclusion that changes in the bioavailability
are not related to differences in the concentrations (within
the range of 10 % to 20 % IgG) or other specific character-
istics of the individual products. Thus, although labeling of
different SCIG products in the US implies that their bio-
availabilities are different, the discrepancies arise from the
fact the licensing studies used “non-inferiority” designs in
which any AUCSCIG/AUCIVIG ratio equal to or above 80 %
was acceptable. As a result, dose adjustments recommended
in the US FDA-approved labels range from 137 % to 153 %
of the monthly IVIG dose [3–6]. Indeed, true AUC equiv-
alence (AUCSCIG/AUCIVIG ≥ 1) was only achieved in one of
the four studies [4].
Fig. 1 Actual bioavailabilities of SCIG products. Bioavailabilities of
Hizentra®, Vivaglobin®, Gamunex®, and Gammagard® are shown.
The mean bioavailability of the four SCIG products is shown with a
horizontal dashed line. Horizontal dotted lines represent SD
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Taken together, the above results suggested the hypothesis
that, if the bioavailabilities of different SCIG products are the
same, the serum IgG concentrations should not change when
patients switch from one SCIG preparation to another at the
same dose. This hypothesis was tested in two prospective
studies, which indeed showed only minimal, clinically irrele-
vant changes in the serum IgG levels when patients were
switched from other preparations to Hizentra®.
Although differences in the kinetics of uptake of IgG into
the circulation following SC vs. IV injection were reported
more than 100 years ago [17], the reasons for the apparent
decrease in overall bioavailability remain unclear. Decreases
in bioavailability similar to those reported here have also
been reported for therapeutic monoclonal antibodies and Fc
fusion proteins [18, 19]. Although one previous study [7]
suggested that the bioavailability of SCIG might be lower in
obese patients with high body mass index (BMI), subse-
quent studies have not confirmed that [3–6]; and a re-
analysis showed that the apparent correlation between bio-
availability and BMI was due to inclusion of a few individ-
uals with extremely low or high BMI [3, 4]. All these
observations suggest that the apparent decrease in bioavail-
ability is an intrinsic property of IgG when it is presented by
the SC rather than the IV route, and is not due to alterations
introduced by the purification or production processes of
any preparation, the concentration of the IgG or the speci-
ficity of the antibodies. We speculate that degradation of
IgG by extracellular proteases, non-covalent binding to the
extracellular matrix, and/or altered access to endothelial cell
neonatal Fc receptor (FcRn), may all contribute to the
Fig. 2 Linear regression analyses of correlation between IgG doses
and trough serum IgG concentration in SCIG- and IVIG-treated PID
patients. Linear trendlines representing the dose-related increase in
trough serum IgG levels in SCIG- and IVIG-treated PID patients are
shown at the same scale to enable comparison (top row). Previously
published analyses are also presented at the original scale (bottom
row). The thick lines represent the portions of the trendlines
corresponding to the data in the original figures. Slope values in mg/dL
per 100 mg/kg/month are indicated next to the trendlines. One retrospec-
tive SCIG study data (Ma; gray circle) was excluded from the trendline
calculation, the others were all prospective. Original figures were repro-
duced with permission from Orange et al., 2012 [14] and Orange et al.,
2010 [13]. The formula used to estimate average SCIG bioavailability is
shown below the graphs
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decreased bioavailability reported for SCIG as compared to
IVIG [2].
In the last few years, many publications have reported
that switching from IVIG to home-based SCIG therapy was
safe, improved the quality of life for PID patients, and had
overall efficacy equal to that of IVIG [7–9, 11, 20]. The US
FDA has chosen to use the AUC as a standard for compar-
ison of SCIG with IVIG and of different SCIG products with
each other. However, most physicians use the trough serum
IgG concentration, obtained just before an IgG dose, as the
preferred pharmacokinetic parameter for evaluating and
adjusting IgG doses. This may be based on the logic that
the total serum IgG level is the sum of individual specific
antibody levels, and the latter determine protection against
new infection at any point in time. Efficacy-dose relation-
ships for both IVIG and SCIG show that, in general, higher
doses result in higher serum IgG levels and increased free-
dom from infection, the major goal of therapy in PID [13,
14, 23]. These studies all focus on the mean results for
groups of patients. However, closer inspection of the results
of any individual study reveals wide variation in the rela-
tionship between serum IgG levels and doses of IgG in
different individual patients with both SC and IV routes of
IgG therapy [1, 20]. Examination of the relationships be-
tween SCIG and IVIG doses and serum IgG levels suggest
that, in general, a monthly dose of SCIG equal to the
monthly dose of IVIG will result in a steady-state IgG level
on SCIG approximately 13 % higher than the trough IgG
level on IVIG [3, 21]. Conversely, the steady-state serum
IgG level on SCIG will be approximately equal to the trough
IgG level on IVIG when the monthly dose of SCIG is 50 %
of the previous monthly IVIG dose [3, 22]. It should be
noted however, that the trough IgG level represents the
lowest serum IgG concentration during any IVIG dosing
interval, and that in most studies of IVIG efficacy, the mean
IgG concentration during any given dosing interval is con-
siderably higher than the trough at the end of that interval.
The mean level across the whole dosing interval, in turn, is
reflected in the AUC. Data on efficacy as a function of
AUC, per se, is not yet available. However, there are data
which suggest that higher steady- state IgG levels on SCIG,
which would correspond to higher AUC values, are associ-
ated with fewer infections and decreased morbidity [14, 23].
Recent studies have clearly shown that different individual
PID patients require different serum IgG concentrations to
remain free from infection [24, 25]. Individualization of
dosing is thus important regardless of which route of ther-
apy is preferred for any given PID patient, but differences in
bioavailability do not suggest a preference for one prepara-
tion of SCIG over another.
Conclusions
In conclusion, our results strongly suggest that decreased
bioavailability appears to be a basic property of SCIG and
not a result of any manufacturing process or concentration.
Because serum IgG levels do not vary with different SCIG
products at the same dose, adjustments are not necessary
when switching products.
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